难治性癫痫致痫区多模态术前检查人工智能辅助诊断系统应用研究

注册号:

Registration number:

ChiCTR2000041530 

最近更新日期:

Date of Last Refreshed on:

2021-03-15 00:44:10 

注册时间:

Date of Registration:

2020-12-27 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

难治性癫痫致痫区多模态术前检查人工智能辅助诊断系统应用研究

Public title:

Application of artificial intelligence diagnosis system for multimodal presurgical epileptogenic zone localization

注册题目简写:

English Acronym:

研究课题的正式科学名称:

难治性癫痫致痫区多模态术前检查人工智能辅助诊断系统应用研究

Scientific title:

Application of artificial intelligence diagnosis system for multimodal presurgical epileptogenic zone localization

研究课题代号(代码):

Study subject ID:

首发2020-1-2013

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

任志伟 

研究负责人:

张国君 

Applicant:

Zhiwei Ren 

Study leader:

Guojun Zhang 

申请注册联系人电话:

Applicant telephone:

+86 13691072803

研究负责人电话:

Study leader's
telephone:

+86 13671233613

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

rzw@xwhosp.org

研究负责人电子邮件:

Study leader's E-mail:

zgj62051@163.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

北京市西城区长椿街45号

研究负责人通讯地址:

北京市西城区长椿街45号

Applicant address:

45 Changchun Street, Xicheng District, Beijing, China

Study leader's address:

45 Changchun Street, Xicheng District, Beijing, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

首都医科大学宣武医院

Applicant's institution:

Xuanwu Hospital of Capital Medical University

研究负责人所在单位:

首都医科大学宣武医院

Affiliation of the Leader:

Xuanwu Hospital of Capital Medical University

是否获伦理委员会批准:

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

临研审[2020]079号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

首都医科大学宣武医院伦理委员会

Name of the ethic committee:

IRB of Xuanwu Hospital of Capital Medical University

伦理委员会批准日期:

Date of approved by ethic committee:

2020-07-29 00:00:00

伦理委员会联系人:

张卓然

Contact Name of the ethic committee:

Zhuoran Zhang

伦理委员会联系地址:

北京市西城区长椿街45号

Contact Address of the ethic committee:

45 Changchun Street, Xicheng District, Beijing, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

首都医科大学宣武医院

Primary sponsor:

Xuanwu Hospital of Capital Medical University

研究实施负责(组长)单位地址:

北京市西城区长椿街45号

Primary sponsor's address:

45 Changchun Street, Xicheng District, Beijing, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

北京

市(区县):

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学宣武医院

具体地址:

西城区长椿街45号

Institution
hospital:

Xuanwu Hospital of Capital Medical University

Address:

45 Changchun Street, Xicheng District

经费或物资来源:

首都卫生发展科研专项项目

Source(s) of funding:

The Capital Health Research and Development of Special Funds

研究疾病:

癫痫  

Target disease:

Epilepsy

研究疾病代码:

Target disease code:

研究类型:

诊断试验

Study type:

Diagnostic test

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

连续入组 

Study design:

Sequential 

研究目的:

完成基于多模态癫痫致痫区辅助定位检查技术的人工智能辅助诊断系统软件应用界面的开发,在多中心(宣武、天坛、儿研所)建立标准化数据采集、预处理流程,在各中心癫痫术前评估临床工作中应用该系统,并联合北京脑重大疾病研究院、北京市神经外科研究所,共5家单位对100例癫痫患者进行辅助诊断致痫区定位,根据实际手术切除部位定位及术后随访结果,验证并不断优化该系统。  

Objectives of Study:

The purpose is to complete the development of software application interface of Artificial Intelligence Aided Diagnosis System Based on multimodal epileptogenic area auxiliary location examination technology, establish standardized data acquisition and preprocessing process in multi centers (Xuanwu, Tiantan, Institute of Pediatrics), and apply the system in clinical work of epilepsy preoperative evaluation in each center, and cooperate with Beijing Institute of major brain diseases and Beijing Institute of Neurology Institute of surgery, a total of 5 units to 100 cases of epilepsy patients with auxiliary diagnosis of epileptogenic area positioning, according to the actual surgical resection location and postoperative follow-up results, verify and constantly optimize the system.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

Inclusion criteria

排除标准:

a. 通过各项致痫区定位检查,癫痫会诊讨论未行致痫区切除的患者;
b. 术后病理结果不属于局灶性皮质发育不良(FCD)、海马硬化、结节性硬化、良性肿瘤其中之一;
c. 手术后一年随访Engle’s III~IV级;
d. 不能完成术后1年随访的患者。

Exclusion criteria:

1. The patients who did not undergo the resection of the epilepsy area were discussed through the location examination and the epilepsy consultation;
2. The postoperative pathological results were not one of focal cortical dysplasia (FCD), hippocampal sclerosis, tuberous sclerosis and benign tumors;
3. Engle's III-IV subjects were followed up one year after operation;
4. Patients who can't complete 1-year follow-up.

研究实施时间:

Study execute time:

From 2020-06-01 00:00:00 To 2023-06-30 00:00:00  

征募观察对象时间:

Recruiting time:

From 2021-01-01 00:00:00 To 2023-06-01 00:00:00

诊断试验:

Diagnostic Tests:

金标准或参考标准(即可准确诊断某疾病的单项方法或多项联合方法,在本研究中用于诊断是否有该病的临床参考标准):

选择术后1年随访手术效果Engel's I级或II级的患者,认为手术切除致痫区位置准确,术后行病理学检查有相应阳性病理学发现,根据手术切除后复查影像学确定切除部位为致痫区定位金标准。

Gold Standard or Reference Standard (The clinical reference standards required to establish the presence or absence of the target condition in the tested population in present study):

We comformed that the location of epileptogenic zone was correct after surgical resection by paitents' 1 year follow-up result of Engel's grade I or II. Positive pathological findings were found after pathological examination site was determined as the gold standard for localization

指标试验(即本研究的待评估诊断试验,无论为方法、生物标志物或设备,均请列出名称):

基于多模态癫痫致痫区辅助定位检查技术的人工智能辅助诊断系统

Index test:

Artificial Intelligence Aided Diagnosis System Based on multimodal epileptogenic area auxiliary location examination technology.

目标人群(可以是某种疾病患者或正常人群,详细描述其疾病特征,注意应纳入符合分布特点的全序列病例,具有良好的代表性)

符合入组标准者

例数:

Sample size:

100

Target condition (The target condition is a particular disease or disease stage that the index test will be intended to identify. Please specify the characteristics in detail; the population should has a complete spectrum and good representative):

Subjects who meet inclusion criteria.

容易混淆的疾病人群(即与目标疾病不易区分的一种或多种不同疾病,应避免采用正常人群对照的病例-对照设计):

例数:

Sample size:

0

Population with condition difficult to distinguish from the target condition, the normal population in a case-control study design should be avoid:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学宣武医院 

单位级别:

三级甲等 

Institution
hospital:

Xuanwu Hospital of Capital Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都医科大学附属北京天坛医院 

单位级别:

三级甲等 

Institution
hospital:

Beijing Tiantan Hospital Affiliated to Capital Medical University

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

首都儿科研究所附属儿童医院 

单位级别:

三级甲等 

Institution
hospital:

Children's Hospital Affiliated to Capital Institute of Pediatrics

Level of the institution:

Tertiary A

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京脑重大疾病研究院 

单位级别:

N/A 

Institution
hospital:

Beijing Institute of Brain Disorders

Level of the institution:

N/A

国家:

中国

省(直辖市):

北京 

市(区县):

 

Country:

China

Province:

Beijing

City:

单位(医院):

北京市神经外科研究所 

单位级别:

N/A 

Institution
hospital:

Beijing Neurosurgical Institute

Level of the institution:

N/A

测量指标:

Outcomes:

指标中文名:

Engel 手术疗效分级

指标类型:

主要指标

Outcome:

Engel surgery outcome classification

Type:

Primary indicator

测量时间点:

术后6 个月,术后1 年

测量方法:

评分量表

Measure time point of outcome:

6 months after surgery, 1 year after surgery

Measure method:

classification scale

指标中文名:

致痫区位置

指标类型:

主要指标

Outcome:

localization of epileptogenic zone

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

癫痫发作频率

指标类型:

主要指标

Outcome:

Change in Seizure Rate

Type:

Primary indicator

测量时间点:

术后6 个月,术后1 年

测量方法:

患者癫痫日记

Measure time point of outcome:

6 months, 1 year after surgery

Measure method:

seizure diary

指标中文名:

癫痫患者生活质量评价

指标类型:

主要指标

Outcome:

quality of life in epilepsy

Type:

Primary indicator

测量时间点:

术后1 年

测量方法:

癫痫患者生活质量评价问卷

Measure time point of outcome:

1 year after surgery

Measure method:

Qolie

指标中文名:

SEN, SPE, ACC, AUC of ROC

指标类型:

主要指标

Outcome:

SEN, SPE, ACC, AUC of ROC

Type:

Primary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

手术病理标本

组织:

致痫区脑组织

Sample Name:

surgical pathological samples

Tissue:

epilepogenic zone brain tissue

人体标本去向

使用后保存  

说明

石蜡切片长期保存

Fate of sample:

Preservation after use  

Note:

Long-term preservation of paraffin sections

征募研究对象情况:

Recruiting status:

正在进行

Recruiting

年龄范围:

Participant age:

最小 Min age 3 years
最大 Max age 60 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

不适用

Randomization Procedure (please state who generates the random number sequence and by what method):

N/A

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

未说明

Blinding:

Not stated

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

是Yes

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

随访结束后6个月,投稿文章,公开原始数据,在相应文章官方网站下载

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

6 months after follow-up, submit articles, publish original data on the official website of the open label journal

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据采集由病例记录表完成,原始数据由宣武医院循证医学中心统一管理

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data collection is completed by the case record form, and the original data is managed by the evidence-based medicine center of Xuanwu Hospital

数据与安全监察委员会:

Data and Safety Monitoring Committee:

有/Yes

注册人:

Name of Registration:

 2020-12-27 21:48:33